8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Nov 26, 2025·SEC
Material company update
May 9, 2025·SEC
Actinium Pharmaceuticals, Inc.(ATNM)Earnings, Financials & Key Ratios
ATNM•AMEX
$1.03
Price updated Jul 7, 2026
AboutActinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple validated cancer targets, including CD45, CD33, CD38, CD47, HER2, and HER3 for targeted conditioning prior to cell and gene therapies, such as bone marrow transplant and cancer therapeutics as single agents or in combination with other therapeutic modalities. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company was incorporated in 2000 and is based in New York, New York.Show more
- Revenue$90K
- EBITDA-$35M+14.2%
- Net Income-$34M+11.4%
- EPS (Diluted)-1.09+14.2%
- Gross Margin100%
- EBITDA Margin-39362.22%
- Operating Margin-40274.44%
- Net Margin-37652.22%
- ROE-166.96%-50.9%
ATNM Price & Volume
Actinium Pharmaceuticals, Inc. (ATNM) stock price & volume — 10-year historical chart
Loading chart...
Persistent Cash Burn Challenges Radiopharmaceutical Development Path
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical and commercial execution
Key Thesis Takeaways
- Actinium Pharmaceuticals faces a precarious financial outlook as it attempts to transition its Iomab-B and ARC platforms toward commercialization while managing a rapidly eroding equity base.
- The company's reliance on sporadic milestone payments and significant stock-based compensation, such as the $8.9 million charge in 2025Q1, obscures the underlying operational losses and complicates long-term valuation.
- Investors should monitor the sustainability of the $35.0 million in deferred revenue and the shrinking cash runway, which declined from $86.0 million in 2024Q2 to $42.1 million by 2026Q1, as these factors remain critical to the firm's ability to reach regulatory milestones.
Verdict Logic
the company's equity base has eroded to just $2.3 million as of 2026Q1, signaling substantial dilution risk and a precarious liquidity position that warrants extreme caution for long-term investors.
ATNM Growth Metrics
Actinium Pharmaceuticals, Inc. (ATNM) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-55.63%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM48.43%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM48.98%
Return on Capital
10 Years-113.14%
5 Years-51.63%
3 Years-60.89%
Last Year-64.41%
ATNM Recent Earnings
Actinium Pharmaceuticals, Inc. (ATNM) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 1/12 qtrs (100%)
Q2 2026Latest
May 8, 2026Metric
Actual
Est
EPS
$0.18+18.2%
$0.22
Rev
—
$3M
Q2 2026
Mar 30, 2026Metric
Actual
Est
EPS
$0.19-1.8%
$0.19
Rev
—
$600,000
Q4 2025
Nov 14, 2025Metric
Actual
Est
EPS
$0.16+36.0%
$0.25
Rev
$90,000+33.3%
$67,500
Q3 2025
Aug 8, 2025Metric
Actual
Est
EPS
$0.22+31.3%
$0.32
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 8, 2026 | $0.18vs $0.22+18.2% | —vs $3M |
| Q2 2026 | Mar 30, 2026 | $0.19vs $0.19-1.8% | —vs $600,000 |
| Q4 2025 | Nov 14, 2025 | $0.16vs $0.25+36.0% | $90,000vs $67,500+33.3% |
| Q3 2025 | Aug 8, 2025 | $0.22vs $0.32+31.3% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Actinium Pharmaceuticals, Inc. (ATNM)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.03 | $32.32M | -0.95 | — | -37652.22% | -166.96% | — | |
| $10.05 | $295.28M | -2.00 | -92.81% | -8550.65% | — | — | |
| $1.92 | $15.61M | -1.60 | — | -90182.27% | — | — | |
| $11.55 | $917.42M | -3.81 | 216.93% | -61.95% | — | — | |
| $0.45 | $66.49M | -0.86 | -3.98% | -1460.9% | -113.15% | — | |
| $6.01 | $2.19B | 19.21 | 43.31% | 7.82% | 7.42% | — |
Compare ATNM vs Peers
Actinium Pharmaceuticals, Inc. (ATNM) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ATNM SEC Filings & Documents
Actinium Pharmaceuticals, Inc. (ATNM) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when ATNM posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ATNM Frequently Asked Questions
Actinium Pharmaceuticals, Inc. (ATNM) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Actinium Pharmaceuticals, Inc.'s revenue?
Actinium Pharmaceuticals, Inc. (ATNM) reported $0.1M in revenue for fiscal year 2025.
Is ATNM profitable?
Actinium Pharmaceuticals, Inc. (ATNM) reported a net loss of $23.5M for fiscal year 2025.
Dividend & Returns
What is ATNM's return on equity?
Actinium Pharmaceuticals, Inc. (ATNM) has a return on equity (ROE) of -167.0%. Negative ROE indicates the company is unprofitable.
What is Actinium Pharmaceuticals, Inc.'s free cash flow?
Actinium Pharmaceuticals, Inc. (ATNM) had negative free cash flow of $23.0M in fiscal year 2025, likely due to heavy capital investments.